Current Oncology Reports

, 13:386

Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma


DOI: 10.1007/s11912-011-0190-z

Cite this article as:
Boyle, E.M. & Morschhauser, F. Curr Oncol Rep (2011) 13: 386. doi:10.1007/s11912-011-0190-z


Rituximab, a monoclonal antibody (mAb) directed against CD20, has changed practices in the treatment of patients with B-cell lymphoma. The large success of rituximab has contributed to validate immunotherapy with monoclonal antibodies as a valuable strategy in lymphoma. Recently, better-engineered anti-CD20-mAbs have been designed to improve efficacy and safety. Also, new antibodies targeting other lymphoma subtypes including T-cell lymphoma and Hodgkin’s disease have been developed. Ongoing pharmacology development is concentrating on immuno-drug-conjugates combining the toxicity of chemotherapy, isotopes, or toxins with the specificity of mAbs. This article offers an overview on the development of new antibodies and immuno conjugates in lymphoma.


Lymphoma Monoclonal antibodies Drug-conjugates Radioimmunotherapy 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of HematologyHôpital Claude Huriez, CHRULilleFrance
  2. 2.EA 4481 GRIIOT, Université de Lille 2Lille, CedexFrance

Personalised recommendations